RT Journal Article
T1 Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease.
A1 Petta, Salvatore
A1 Sebastiani, Giada
A1 Viganò, Mauro
A1 Ampuero, Javier
A1 Wai-Sun Wong, Vincent
A1 Boursier, Jerome
A1 Berzigotti, Annalisa
A1 Bugianesi, Elisabetta
A1 Fracanzani, Anna Ludovica
A1 Cammà, Calogero
A1 Enea, Marco
A1 Grottes, Marraud des
A1 Di Marco, Vito
A1 Younes, Ramy
A1 Keyrouz, Aline
A1 Mazzola, Sergio
A1 Mendoza, Yuly
A1 Pennisi, Grazia
A1 Romero-Gomez, Manuel
A1 Craxì, Antonio
A1 de Ledinghen, Victor
K1 NASH
K1 Prognostic Factor
K1 Steatohepatitis
K1 cACLD
AB Patients with advanced fibrosis related to nonalcoholic fatty liver disease (NAFLD) are at risk of developing hepatic and extrahepatic complications. We investigated whether, in a large cohort of patients with NAFLD and compensated advanced chronic liver disease, baseline liver stiffness measurements (LSMs) and their changes can be used to identify patients at risk for liver-related and extrahepatic events. We performed a retrospective analysis of consecutive patients with NAFLD (n = 1039) with a histologic diagnosis of F3-F4 fibrosis and/or LSMs>10 kPa, followed for at least 6 months, from medical centers in 6 countries. LSMs were made by FibroScan using the M or XL probe and recorded at baseline and within 1 year from the last follow-up examination. Differences between follow up and baseline LSMs were categorized as: improvement (reduction of more than 20%), stable (reduction of 20% to an increase of 20%), impairment (an increase of 20% or more). We recorded hepatic events (such as liver decompensation, ascites, encephalopathy, variceal bleeding, jaundice, or hepatocellular carcinoma [HCC]) and overall and liver-related mortality during a median follow-up time of 35 months (interquartile range, 19-63 months). Based on Cox regression analysis, baseline LSM was independently associated with occurrence of hepatic decompensation (hazard ratio [HR], 1.03; 95% CI, 1.02-1.04; P  In patients with NAFLD and compensated advanced chronic liver disease, baseline LSM and change in LSM are associated with risk of liver-related events and mortality.
YR 2020
FD 2020-07-02
LK http://hdl.handle.net/10668/15875
UL http://hdl.handle.net/10668/15875
LA en
DS RISalud
RD Apr 9, 2025